<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gonzales MM</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>NIA NIH HHS</funding><funding>National Institute on Aging</funding><pagination>e12298</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8943903</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>&lt;b>Introduction&lt;/b>: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. &lt;b>Methods&lt;/b>: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). &lt;b>Results&lt;/b>: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia ri</pubmed_abstract><journal>Alzheimer's &amp; dementia (Amsterdam, Netherlands)</journal><pubmed_title>Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.</pubmed_title><pmcid>PMC8943903</pmcid><funding_grant_id>AG059421</funding_grant_id><funding_grant_id>AG054076</funding_grant_id><funding_grant_id>P30 AG059305</funding_grant_id><funding_grant_id>NS100605</funding_grant_id><funding_grant_id>DP1 AG069870</funding_grant_id><funding_grant_id>P30 AG066546</funding_grant_id><funding_grant_id>R01 AG066524</funding_grant_id><funding_grant_id>AG066546</funding_grant_id><pubmed_authors>Royall DR</pubmed_authors><pubmed_authors>Gonzalez DA</pubmed_authors><pubmed_authors>Zare H</pubmed_authors><pubmed_authors>O'Bryant S</pubmed_authors><pubmed_authors>Parent DM</pubmed_authors><pubmed_authors>Wang CP</pubmed_authors><pubmed_authors>Satizabal CL</pubmed_authors><pubmed_authors>Short MI</pubmed_authors><pubmed_authors>Seshadri S</pubmed_authors><pubmed_authors>Maestre GE</pubmed_authors><pubmed_authors>Kautz T</pubmed_authors><pubmed_authors>Gonzales MM</pubmed_authors><pubmed_authors>Tracy RP</pubmed_authors><pubmed_authors>MacCarthy D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort.</name><description>&lt;b>Introduction&lt;/b>: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. &lt;b>Methods&lt;/b>: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). &lt;b>Results&lt;/b>: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia ri</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T07:33:38.624Z</modification><creation>2025-04-04T07:33:38.624Z</creation></dates><accession>S-EPMC8943903</accession><cross_references><pubmed>35356487</pubmed><doi>10.1002/dad2.12298</doi></cross_references></HashMap>